Cracking complexity: Leveraging lessons learned for future bispecific development

The biologics pipeline is becoming increasingly complex as next-generation antibody formats, including bispecific antibodies (BsAbs), move rapidly toward the clinic. For early-stage biotech teams, this complexity often translates into uncertainty around where the true development risks materialize, how early decisions influence IND readiness, and how to progress quickly without creating downstream rework.